Early patient data suggests that FlowOx™ may have a role in Multiple Sclerosis (MS) symptoms management

Preliminary results from an exploratory pilot investigation carried out by Neuro-SysMed, Norway’s leading center of excellence in Neurological research, were presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)¹.

Based on the promising results from the pilot study at Haukeland, Otivio and NeuroSysmed decided to initiate a larger randomized controlled trial in Scandinavia.

¹ www.ectrims.eu

First RCT to show improved walking capacity

First multi-centre randomized controlled trial using FlowOx™, published in Journal of Vascular Surgery, shows improved walking capacity for patients with intermittent claudication, also known as “windows shopper’s disease”.

Is FlowOx™ for me?

What is FlowOx™?

A revolutionary new technology for the treatment of reduced peripheral micro circulation

How does it work?

FlowOx™ works by exercising the blood vessels from the small arteries to the capillaries in the outer layers of the skin.

Who can benefit from using FlowOx™?

FlowOx™ is recommended for patients of over 18 years who suffer from blood flow deficiencies in the lower limbs such as:

a) Peripheral arterial disease (PAD),
b) Diabetic and non-diabetic arteriopathic foot and leg ulcers,
c) Intermittent claudication and rest pain,
d) Foot and lower leg ulcers of mixed aetiology and/or pain/spasticity or discomfort associated with immobility such as paraplegia following spinal cord injury or other neurodegenerative diseases such as multiple sclerosis.

Can FlowOx™ be integrated into an existing therapy?

FlowOx™ is an additional treatment and can be used in conjunction with standard care (typical wound care and medication).

Without FlowOx™ I would have lost my other leg as well and I am not sure I would have been here today. That is what FlowOx™ has done for me..
Stine, Norway

Listen to Stine’s and Hans Thomas’ stories

Stine’s own story

First FlowOx™ patient, Hans Thomas

OTIVIO

FlowOx™ by Otivio

Otivio AS is a Norwegian medtech company based in Oslo. FlowOx™ is a non-invasive medical device for home treatment addressing insufficient blood flow to the limbs associated with peripheral arterial disease, diabetes and other arterial blood flow deficiencies. FlowOx™ is documented to reduce or eliminate these outcomes which represent a big impact on Quality of Life and health care costs. FlowOx™ is CE marked (CE2460) and available in various countries.